老年与年轻胃癌患者围手术期治疗对比:CRITICS试验结果
CRITICS试验纳入788例可切除胃癌患者,随机接受术前化疗后手术,术后化疗或放化疗。老年(≥70岁)患者术前严重毒性发生率更高且化疗相对剂量强度更低,术后治疗启动比例更低,但两组根治性手术比例、术后并发症及2年无事件生存率相当。
要点
- 老年胃癌患者围手术期治疗依从性较差,尤其术后阶段。
- 老年患者术前化疗严重毒性更高,相对剂量强度更低。
- 两组根治性手术比例和2年无事件生存率相当。
核心结论
- 老年(≥70岁)胃癌患者围手术期治疗依从性较年轻患者差,尤其在术后阶段。
研究设计与样本
- CRITICS试验为随机对照试验,共纳入788例可切除胃癌患者,随机接受术前化疗(表柔比星+顺铂或奥沙利铂+卡培他滨,3周期),手术后行术后化疗或放化疗(45Gy+顺铂+卡培他滨)。
主要发现
- 术前化疗期间,老年组131例(77%)发生严重毒性,年轻组380例(62%),p<0.001;老年组所有化疗药物相对剂量强度显著更低。
- 根治性手术比例老年组137例(80%)与年轻组499例(81%)相当,术后并发症和术后死亡率可比。
- 根治性手术后术后治疗启动比例老年组87例(64%)低于年轻组391例(78%),p<0.001。
- 术后化疗严重毒性发生率老年组22例(54%)与年轻组113例(59%)无显著差异(p=0.541),但老年组所有化疗药物相对剂量强度显著更低。
- 术后放化疗严重毒性发生率老年组22例(48%)与年轻组89例(45%)无显著差异(p=0.703),化疗相对剂量强度和放疗剂量可比;2年无事件生存率老年组53% vs 年轻组51%。
临床怎么用
- 老年胃癌患者围手术期治疗需关注术前毒性及剂量强度,术后治疗启动率较低,应加强支持管理以提高依从性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To evaluate treatment-related toxicity, treatment compliance, surgical complications and event-free survival (EFS) in older (≥70 years) versus younger (<70 years) adults who underwent perioperative treatment for gastric cancer. METHODS: In the CRITICS trial, 788 patients with resectable gastric cancer were randomised before start of any treatment and received preoperative chemotherapy (3 cycles of epirubicin, cisplatin or oxaliplatin and capecitabine), followed by surgery, followed by either postoperative chemotherapy or chemoradiotherapy (45Gy + cisplatin + capecitabine). RESULTS: 172 (22%) patients were older adults. During preoperative chemotherapy, 131 (77%) older adults versus 380 (62%) younger adults experienced severe toxicity (p < 0.001); older adults received significantly lower relative dose intensities (RDIs) for all chemotherapeutic drugs. Equal proportions of older versus younger adults underwent curative surgery: 137 (80%) versus 499 (81%), with comparable postoperative complications and postoperative mortality. Postoperative therapy after curative surgery started in 87 (64%) older adults versus 391 (78%) younger adults (p < 0.001). Incidence of severe toxicity during postoperative chemotherapy was 22 (54%) in older adults versus 113 (59%) in younger adults (p = 0.541); older adults received significantly lower RDIs for all chemotherapeutic drugs. Severe toxicity rates for postoperative chemoradiotherapy were 22 (48%) older adults versus 89 (45%) for younger adults (p = 0.703), with comparable chemotherapy RDIs and radiotherapy dose. Two-year EFS was 53% for older adults versus 51% for younger adults. CONCLUSION: Perioperative treatment compliance, especially in the postoperative phase, was poorer in older adults compared with younger adults. As comparable proportions of patients underwent curative surgery, future studies should focus on neo-adjuvant treatment. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00407186. EudraCT number: 2006-00413032.
引用
- Slagter AE, Tudela B, van Amelsfoort RM, et al. Older versus younger adults with gastric cancer receiving perioperative treatment: Results from the CRITICS trial. Eur J Cancer. 2020. PMID: 32208351. doi:10.1016/j.ejca.2020.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。